21+
Age Verification
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
You must be 21 years of age or older to enter this site.
By entering, you confirm you are 21 years of age or older.
Tesamorelin is a synthetic 44-amino acid peptide analogue of human growth hormone-releasing hormone (GHRH 1-44) featuring an N-terminal trans-3-hexenoic acid modification. This structural modification enhances the peptide's metabolic stability and resistance to enzymatic degradation compared to native GHRH, resulting in a prolonged pharmacokinetic profile in preclinical models.
The compound acts as a selective agonist at the GHRH receptor (GHRHR), stimulating pituitary somatotroph cells to produce and release growth hormone through the same physiological signaling cascade as endogenous GHRH. Tesamorelin has been extensively characterized in multiple published clinical studies and is the subject of ongoing research investigating its receptor binding kinetics and downstream signaling effects.
AXOM Tesamorelin is manufactured under strict cGMP-equivalent protocols and verified to ≥99% purity via reverse-phase HPLC. Each lot is accompanied by a Certificate of Analysis documenting identity, purity, peptide content, and endotoxin levels. Available as a 10mg lyophilized powder. For research and laboratory use only.
Full-length 44-amino acid GHRH analogue with N-terminal trans-3-hexenoic acid conjugation for enhanced metabolic stability in research applications.
Trans-3-hexenoic acid modification provides improved resistance to enzymatic degradation compared to native GHRH, extending the compound's activity profile.
≥99% HPLC-verified purity with full COA documentation. Every lot independently tested by third-party analytical laboratories.
Pooled analysis of two Phase 3 studies characterizing tesamorelin's pharmacodynamic profile, including its sustained GHRH receptor engagement and dose-dependent effects on the GH/IGF-I axis over 26 weeks in controlled settings.
Randomized study examining tesamorelin's GHRH receptor agonist activity and its downstream effects on GH pulsatility patterns. Documents the compound's selective mechanism of action at the pituitary level with preserved hypothalamic-pituitary feedback regulation.
Comprehensive review of tesamorelin's molecular structure, receptor binding characteristics, pharmacokinetic parameters, and preclinical activity data. Provides detailed analysis of the trans-3-hexenoic acid modification and its contribution to the compound's enhanced stability profile.
| Product Name | Tesamorelin (Modified GHRH 1-44) |
| Synonyms | TH9507, Egrifta |
| CAS Number | 218949-48-5 |
| Molecular Formula | C221H366N72O67S |
| Molecular Weight | ~5,135.89 Da |
| Sequence Length | 44 amino acids |
| Modification | N-terminal trans-3-hexenoic acid conjugation |
| Receptor Target | GHRH Receptor (GHRHR) — selective agonist |
| Purity | ≥99% (Reverse-Phase HPLC) |
| Form | Lyophilized white powder |
| Available Size | 10mg |
| Solubility | Soluble in sterile water, bacteriostatic water |
| Endotoxin | <1 EU/μg (LAL method) |
| Certification | COA included with every order |
| Intended Use | For research and laboratory use only |
Tesamorelin is supplied as a lyophilized powder and should be reconstituted with sterile bacteriostatic water (BAC water) for research applications.
All orders ship within the continental United States via USPS or UPS. Peptides are shipped at ambient temperature — lyophilized peptides are stable during transit. Free shipping on orders over $250.
